Maryland State Retirement & Pension System Sells 5,042 Shares of TransMedics Group, Inc. $TMDX

Maryland State Retirement & Pension System lessened its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 50.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,901 shares of the company’s stock after selling 5,042 shares during the quarter. Maryland State Retirement & Pension System’s holdings in TransMedics Group were worth $550,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Amalgamated Bank lifted its position in TransMedics Group by 0.8% during the second quarter. Amalgamated Bank now owns 9,586 shares of the company’s stock valued at $1,285,000 after purchasing an additional 80 shares in the last quarter. Canada Pension Plan Investment Board increased its position in TransMedics Group by 2.9% in the second quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock worth $482,000 after buying an additional 100 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in shares of TransMedics Group by 24.5% in the second quarter. Smartleaf Asset Management LLC now owns 548 shares of the company’s stock worth $72,000 after buying an additional 108 shares during the period. CWM LLC lifted its position in shares of TransMedics Group by 18.5% during the 3rd quarter. CWM LLC now owns 897 shares of the company’s stock valued at $101,000 after buying an additional 140 shares in the last quarter. Finally, Ameritas Investment Partners Inc. grew its stake in shares of TransMedics Group by 4.4% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,394 shares of the company’s stock valued at $455,000 after acquiring an additional 142 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Price Performance

TMDX stock opened at $138.09 on Friday. TransMedics Group, Inc. has a 52 week low of $58.54 and a 52 week high of $156.00. The firm has a market capitalization of $4.72 billion, a P/E ratio of 55.91 and a beta of 2.03. The company has a fifty day simple moving average of $132.43 and a two-hundred day simple moving average of $122.93. The company has a quick ratio of 7.13, a current ratio of 7.69 and a debt-to-equity ratio of 1.43.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.29. The firm had revenue of $143.82 million for the quarter, compared to the consensus estimate of $145.33 million. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The business’s quarterly revenue was up 32.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.12 EPS. Analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Insider Buying and Selling

In other TransMedics Group news, insider Anil P. Ranganath sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total transaction of $435,660.00. Following the sale, the insider directly owned 13,955 shares in the company, valued at $2,026,545.10. This represents a 17.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Edward M. Basile sold 4,142 shares of the firm’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $130.45, for a total value of $540,323.90. Following the completion of the sale, the director directly owned 2,866 shares of the company’s stock, valued at $373,869.70. The trade was a 59.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 13,062 shares of company stock valued at $1,797,634. Insiders own 7.00% of the company’s stock.

Analysts Set New Price Targets

TMDX has been the subject of several analyst reports. Morgan Stanley increased their target price on shares of TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 2nd. Needham & Company LLC upped their price target on shares of TransMedics Group from $148.00 to $166.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Zacks Research downgraded shares of TransMedics Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Canaccord Genuity Group lifted their target price on shares of TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Finally, Jefferies Financial Group assumed coverage on TransMedics Group in a research note on Monday, October 13th. They issued a “buy” rating and a $145.00 price target for the company. Six equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $144.25.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.